SPONSOR
Shanghai AbelZeta Ltd.
Total Trials
2
Recruiting
2
Phases
Phase 1, Phase 2, Phase 1
Shanghai AbelZeta Ltd. is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Relapsed/Refractory Large B-Cell Lymphoma, Squamous Cell Lung Cancer.
The trial portfolio spans Phase 1, Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Shanghai AbelZeta Ltd.
How many clinical trials has Shanghai AbelZeta Ltd. sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Shanghai AbelZeta Ltd., of which 2 are actively recruiting participants. These trials cover conditions including Relapsed/Refractory Large B-Cell Lymphoma, Squamous Cell Lung Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Shanghai AbelZeta Ltd. research focus on?
Shanghai AbelZeta Ltd. clinical trials span Relapsed/Refractory Large B-Cell Lymphoma, Squamous Cell Lung Cancer. The research pipeline includes Phase 1, Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Shanghai AbelZeta Ltd. clinical trial?
To participate in a Shanghai AbelZeta Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Shanghai AbelZeta Ltd. trials with current recruitment status updated daily.
Clinical Trials by Shanghai AbelZeta Ltd.
NCT05800977 Phase 1, Phase 2
Recruiting
A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
Relapsed/Refractory Large B-Cell Lymphoma
NCT07444281 Phase 1
Recruiting
An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer
Squamous Cell Lung Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology